Retension Pharmaceuticals, Inc. (RTSN) stock
RTSNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 18, 2026
$10.51−2.50 (-19.22%)
Close on Nov 20, 2026Market cap $8.49MP/E –Yield –
Retension Pharmaceuticals net income
Net income is the profit left for shareholders after every expense, interest and tax.
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$5.92M | – |
| Q2 FY2026 | Jun 30, 2026 | -$4.14M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.38M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.48M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.23M | – |
| Q1 FY2025 | Mar 31, 2025 | -$656.50K | – |
See a number that looks wrong?